No effect of predicted donor NK alloreactivity on the clinical outcome of haploidentical HSCT in our patient series. Cumulative incidence of relapse of underlying disease (gray lines) and TRM (black lines) in patients with (dashed lines, n = 23) and without (full line, n = 20) predicted NK alloreactivity. P values were estimated by a competing risk analysis.